Dr. David T. Steele, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Mississippi School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 387
Licensed in Alabama since 2018, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Mississippi School of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
AL license 36538 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Grandview Medical Center Birmingham, AL
- Coosa Valley Medical Center Sylacauga, AL
Medical groups
- Birmingham Gastroenterology Associates PC (53 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 387
- Services billed
- 12,881
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 1,247 | 117 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 719 | 118 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 240 | 39 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 166 | 33 |
| Established patient office or other outpatient visit, 30-39 minutes | 96 | 80 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 76 | 76 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 59 | 57 |
| New patient office or other outpatient visit, 45-59 minutes | 48 | 48 |
| Biopsy of large bowel using a flexible endoscope | 27 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 20 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Birmingham, AL | 242 |
| Plenvu (peg3350/sod sul/nacl/kcl/asb/c) | 110 |
| Omeprazole Other prescribers in Birmingham, AL | 74 |
| Famotidine Other prescribers in Birmingham, AL | 72 |
| Linzess (linaclotide) Other prescribers in Birmingham, AL | 62 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Birmingham, AL | 56 |
| Sutab (sod sulf/pot chloride/mag sulf) | 52 |
| Dicyclomine Hcl Other prescribers in Birmingham, AL | 44 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Birmingham, AL | 43 |
| Mesalamine Other prescribers in Birmingham, AL | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 100 payments worth $23,769 in total to this clinician.
| Janssen Biotech, Inc. | $22,294 |
|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358 |
| Lilly USA, LLC | $307 |
| AbbVie Inc. | $266 |
| Qol Medical, LLC | $136 |
| Ardelyx, Inc. | $92.14 |
| Celltrion USA Inc. | $72.85 |
| Phathom Pharmaceuticals, Inc. | $49.64 |
| Compensation for services other than consulting (speaking, faculty) | $19,388 |
|---|---|
| Food and Beverage | $2,301 |
| Travel and Lodging | $2,080 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 3, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,850 |
| Janssen Biotech, Inc. Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,745 |
| Janssen Biotech, Inc. Sep 6, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,475 |
| Janssen Biotech, Inc. May 17, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,475 |
| Janssen Biotech, Inc. Feb 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,408 |
| Janssen Biotech, Inc. Feb 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,408 |
| Janssen Biotech, Inc. Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $1,100 |
| Janssen Biotech, Inc. Feb 4, 2025 | Travel and Lodging TREMFYA · Immunology · travel to HUNTSVILLE, AL · in-kind | $789 |
| Janssen Biotech, Inc. Apr 29, 2025 | Travel and Lodging TREMFYA · Immunology · travel to MONTGOMERY, AL · in-kind | $717 |
| Janssen Biotech, Inc. Jul 19, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $688 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Oct 25, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $1,100 |
| Janssen Biotech, Inc. Sep 6, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,475 |
| Janssen Biotech, Inc. Jul 19, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $688 |
| Janssen Biotech, Inc. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $239 |
| Janssen Biotech, Inc. May 17, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,475 |
| Janssen Biotech, Inc. May 3, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,850 |
| Janssen Biotech, Inc. Apr 29, 2025 | Travel and Lodging TREMFYA · Immunology · travel to MONTGOMERY, AL · in-kind | $717 |
| Janssen Biotech, Inc. Feb 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,408 |
| Janssen Biotech, Inc. Feb 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,408 |
| Janssen Biotech, Inc. Feb 20, 2025 | Travel and Lodging TREMFYA · Immunology · travel to BESSEMER, AL · in-kind | $574 |
| Janssen Biotech, Inc. Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,745 |
| Janssen Biotech, Inc. Feb 4, 2025 | Travel and Lodging TREMFYA · Immunology · travel to HUNTSVILLE, AL · in-kind | $789 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $68,538 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. · Completed · NCT01848561 - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.